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ABSTRACT: A new [3 + 3]- and [3 + 4]-annulation strategy
involving azaoxyallyl cation and [1,m]-amphoteric compounds
(m = 3,4) is presented. This concise method enables easy
assembly of functionalized saturated N-heterocycles, com-
prised of six-and seven-membered rings and is of high
significance in the context of drug discovery approaches.
This reaction also represents a new trapping modality of the
azaoxyallyl cation with amphoteric agents of different chain
lengths that consist of a heteroatom nucleophilic site and a π-
electrophilic site.
■ INTRODUCTION
Use of saturated N-heterocycles of different ring sizes has
become indispensable in the current paradigm of the drug
discovery and development efforts.1 Their significance and
wide utility demand continuous feeding of new synthetic
strategies that can address key synthetic challenges such as
one-step convergent access to the functionalized core
structures including those with the medium-sized ring.2−5
Several groups including Bode,2a,5 Aggarwal,3 and Carreira4
have sought to identify practicable solutions to the existing
shortcomings, and some important advances were made in
recent years through development of distinct intermolecular
and intramolecular approaches (Scheme 1a).2−6 Bode’s
development of SnAP reagents is particularly noteworthy as
it allows one-step generation of a range of functionalized,
medium-sized (six to nine membered rings) saturated N-
heterocycles.
Among the saturated N-heterocycles, morpholine and 1,4-
oxazepane are some of the most abundant motifs featured in
many pharmaceuticals and basic skeleton of natural products.7
We envisaged that the −C(CO)N− molecular skeleton of a
putative azaoxyallyl cation could be a potential synthon to
forge the aforementioned classes of heterocycles upon
successfully engaging complementary annulation partners in
the reaction.
In recent years, strategic uses of azaoxyallyl cation chemistry
have emerged as a powerful tool for the assembly of N-
containing heterocycles through development of various [3 +
1], [3 + 2], [3 + 3], and [3 + 4] cycloadditions.8−10 These
reactions involved a range of dipolarophiles, 1,3-dipolar
compounds, and ylides as the reaction partners (Scheme 1b).
Kinetically amphoteric molecules represent an interesting
compound class, where the nucleophilic and electrophilic
sites are intercepted by certain number of atoms and not linked
mesomerically (generally termed as [1,m] systems).11 We
surmised that reaction of azaoxyallyl cation with amphoteric
molecules possessing a nucleophilic heteroatom center and a π-
electrophilic site12 could lead to a new strategy for N-
heterocycles that would not only complement the pre-existing
methods but also resolve some of the unmet challenges within
the context. This facet of reaction development however
remained largely unexplored till date.
In line of our interest to develop new reactions with the
azaoxyallyl cation,13 we herein disclose the design and
development of [3 + 3] and [3 + 4]-annulation of azaoxyallyl
cation with 1,3- and 1,4-amphoteric reagents for efficient
synthesis of important saturated N-heterocyclic systems such
as morpholines and 1,4-oxazepanes derivatives. Importantly,
our approach allows ring-size variations in the final products by
varying the chain length of same class of reaction partner,
which is rarely demonstrated in the realm of azaoxyallyl cation
chemistry.
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■ RESULTS AND DISCUSSION
At the outset of the study, we chose azaoxyallyl cation
precursor 1a and amphoteric agent 2a as model substrates
while being mindful of the following possible obstacles; (1)
azaoxyallyl cation shows remarkable stability in small-molecule
alcohols8,9d,g (MeOH, EtOH, iPrOH, hexafluoro-2-propanol
(HFIP), and TFE are routinely used as the solvent in the
reaction of azaoxyallyl cation), imparting the challenge
associated with participation of the hydroxyl site of 2a, (2)
chemoselectivity issues because of the presence of other
“azaoxyallyl cation-reactive” dipolarophiles such as carbonyl
and olefin units, within the skeletal structure of 2a,9e,f,i (3) base
sensitivity of 2a-like compounds and propensity for self-
reaction/isomerization.14 Fluorinated solvents usually offer
better stability of azaoxyallyl cation,10f which prompted us to
begin our investigations with model substrates 1a (1.0 equiv)
and 2a (1.0 equiv) in HFIP, and Et3N (2.0 equiv) was used as
the base (Table 1).
Pleasingly, under this reaction condition, desired product
3aa was obtained in 30% yield (entry 1). However, HBr
elimination from 1a was identified as the major side reaction
together with some minor quantity of dimer from 2a. Adding
2.0 equiv of 1a in the reaction slightly improved the yield
(entry 2). Although use of the other organic bases rendered
better conversions (entries 3−4), it also accompanied non
negligible side-product formation, which entailed difficult
chromatographic separation. On the contrary, inorganic bases
afforded much cleaner conversion (entries 5−6), and up to
76% yield of desired product could be achieved with Na2CO3
when 2.0 equiv of 1a was used (entry 7). Best performance was
recorded with 3.0 equiv of Na2CO3 (entry 8). Results turned
inferior upon performing the reaction at lower concentration
or with 4.0 equiv of base (entries 9−10 vs entry 8). Other
choices of organic solvent and base were only moderately
effective for this transformation (entries 11−14). The product
structure and hence the desired site selectivity were confirmed
by NMR analysis; the absence of olefinic proton signal in the
product, appearance of keto-methylene proton resonances at
3.47 and 3.34 ppm, and a carbonyl resonance at 197.7 ppm in
13C NMR were in agreement with the structure 3aa.
With the optimized reaction conditions in hand, we next
proceeded to examine the substrate scope (Scheme 2).
Different substitution on the aromatic ring of 2 was evaluated
first. Electron-releasing groups present at ortho, meta, and para
positions and halogens at the para position worked favorably
and afforded high yields (3ab−3ag). An aromatic ring with
extended π-framework could also be accommodated in the
product (3ah). While some further variations on the α-
halohydroxamate moiety such as methoxy group on nitrogen
atom (3bh) or cyclohexyl group at the α-position (3ch) were
tolerated, use of unsubstituted or monomethyl or phenyl
substituted compounds was unsuccessful (3da−3fa). In the
later cases, starting materials were mostly unreacted, and no
trace of the desired product was observed by NMR and MS
analysis. Compound 2 with an aliphatic ketone residue was
compatible in the reaction, although a slight drop in the yield
was recorded (3ai). Gram scale preparation of 3aa was
achieved with 91% yield, which highlights the practicability of
the current method.
To further expand the scope of the transformation, we next
investigated another amphoteric agent 4a that contained an
alkynone unit as the electrophilic counterpart (Scheme 3).
Gratifyingly, this [3 + 3]-annulation also proceeded smoothly
under the optimized reaction conditions and afforded 5aa in
68% yield with complete Z-selectivity of the olefin. Notably,
such morpholine derivatives with an exocyclic vinylogous
amide moiety embedded within are important intermediates
for the synthesis of alkaloid natural products.15 This trans-
formation also tolerated a broad range of substituent variation
on 4, leading to cyclic products 5ab−5ae. Interestingly,
compound 4f possessing a methyl ketone residue reacted
differently. In this case, a secondary [3 + 2]-annulation
Scheme 1. Previous Studies and Our Approach Table 1. Optimization of [3 + 3]-Annulation Reactiona
entry base equiv solvent yield (%)b
1c Et3N 2.0 HFIP 30
2 Et3N 2.0 HFIP 40
3 DBU 2.0 HFIP 45
4 DIPA 2.0 HFIP 60
5c K2CO3 2.0 HFIP 58
6c Na2CO3 2.0 HFIP 62
7 Na2CO3 2.0 HFIP 76
8 Na2CO3 3.0 HFIP 95
9d Na2CO3 3.0 HFIP 80
10 Na2CO3 4.0 HFIP 78
11 Na2CO3 3.0 CH3CN 55
12 Na2CO3 3.0 CH2Cl2 52
13 Na2CO3 3.0 THF 28
14 Na2CO3 3.0 HFIP 55
aReaction conditions: 1a (2.0 equiv), 2a (1.0 equiv), base (3.0 equiv)
solvent (0.2 M), reaction time (6−8 h). bYields of the isolated
products. c1.0 equiv. of 1a was used. dReaction concentration was 0.1
M.
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involving the ketone moiety occurred subsequent to the
desired [3 + 3]-annulation step, which afforded 6 as the major
product (59%). The desired [3 + 3]-annulated product could
be isolated only as inseparable product mixture with 6, which
was corroborated via NMR analysis. This fact definitively
confirmed the occurrence of a [3 + 3]-annulation first,
followed by the [3 + 2]-annulation. Notably, use of equimolar
ratio of 1a and 4f did not alter the outcome significantly.
NMR studies of compounds 5 revealed some interesting
observations that warrant further investigations. For example,
the vinylic proton signal of compound 5ab was completely
shifted from 5.29 ppm, which was recorded for the freshly
prepared sample, to 6.71 ppm upon standing overnight (ca. 24
h) in CDCl3. The benzyloxy and −OCH2 methylene protons
were also distinctly shifted. The nuclear Overhauser effect
(NOE) analysis (see Scheme S1 in the Supporting
Information) confirmed the (Z)-configuration of the olefin
for initially formed product (kinetically controlled) which was
set during [3 + 3]-annulation step, and the later compound
was the isomerized (E)-isomer of 5ab. The NOE studies
further indicated s-cis orientation of CC−CO single bond
in both the cases.
Importantly, the related compound with a free NH group
(e.g., 5ab in Scheme S1 and 5aa′ in Scheme S2 in Supporting
Information) usually favors (Z)-isomer in equilibrium because
of intramolecular hydrogen bonding.15,16 In contrast, density
functional theory (DFT) calculations indicated a reverse trend
for compounds with a substituted nitrogen, such as 5aa. In this
case, the (Z)-isomer was found to be 7.3 kcal mol−1 higher in
energy compared to the (E)-isomer (Scheme 4a).17 A plausible
mechanism for initial formation of (Z)-isomer of compound 5
and its subsequent isomerization is outlined in Scheme 4b. We
speculated that, during the 6-exo-dig ring-closure with N-
benzyloxy group leading to 5, the protonation step of the
Scheme 2. Substrate Scope for the [3 + 3]-Annulation of Hydroxyl-Alkenones and α-Halo Hydroxamates
Scheme 3. [3 + 3]-Annulation of Hydroxyl-Alkynone with
α-Halo Hydroxamatesa
aReaction conditions: α-bromo hydroxamate 1 (2.0 equiv), hydroxyl
alkynones 4 (1.0 equiv), Na2CO3 (3.0 equiv) in (CF3)2CHOH (0.2
M), and reaction time (6−8 h).
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putative vinylic carbanion locked the ensuing olefin residue in
its Z-configuration. Strong hydrogen-bond donor ability of
HFIP most likely facilitated this process and overrode the
steric effect through formation of a favorable hydrogen bonded
transition state (Scheme 4b).
In the presence of catalytic acid (CDCl3 or 10 mol % p-
TsOH), push−pull protonation at the oxygen center of the
vinylogous amide moiety18 and single-bond rotation trans-
formed the (Z)-isomer to the more stable (E)-5.
After having established the unified [3 + 3]-annulation of
azaoxyallyl cation with two different 1,3-amphoteric agents to
functionalized morpholine derivatives, we next embarked on a
more daunting task to develop a [4 + 3]-annulation by
employing 1,4-amphoteric agents 7 for the preparation of
various seven-membered 1,4-oxazepanes (Scheme 5). Syn-
thesis of medium-sized heterocycles via [4 + 3] cycloaddition
is a challenging endeavor, and only one such cycloaddition is
known for azaoxyallyl cation with cyclic dienes as the reaction
partner.10f
Initial reaction of 1a with 7a under the optimized conditions
proved futile. Side-product formation from 1a and unreacted
7a were only detected in the reaction mixture. To our
satisfaction, elevated reaction temperature (60 °C) favored the
desired annulation process and afforded seven-membered 1,4-
oxazepane derivative 8aa in good yield (67%). The structure of
the product was unambiguously determined by X-ray crystal
structure analysis. This reaction also displayed a broad
substrate scope; compound 7 with varied aromatic substitu-
tions (8ab−8af) or with naphthyl and thiophene moieties were
competent (8ag−8ah, 8bh).
Scope and limitations of the transformation with other
closely related 1,4-amphoteric systems such as compound 9
and 12 were next investigated (Scheme 6). These systems were
analogous to compound 7 by virtue of the presence of
nucleophilic hydroxyl site and π-centered electrophilic site
within the molecular skeleton, but these were embedded in a
distinct electronic and steric environment to that of compound
7. Curiously, reaction of 1a with 9a or 9b only afforded acyclic
compounds 10a−b. Cyclization of 10a and 10b to compounds
11a−b however could be achieved, after few optimization
trials, with Et3N in MeOH at 60 °C. Another related
compound 12 was primarily reacted through the carbonyl
moiety and afforded 13 (65%) as the major product along with
some O-alkylated product (14).
The utility of our method was further demonstrated via
synthetic elaboration of some selected compounds prepared
herein into important and synthetically challenging fused bi-
and tricyclic systems (Scheme 7). For example, hydrogenolysis
of 3aa with Pd/C furnished 15 (48%), which was cyclized
under Mitsunobu condition19 to afford compound 16 (68%) as
a single diastereomer. Relative stereochemistry of 16 was
established by NOE experiments. In another case, the
benzyloxy group of 8af was first deprotected with Mo(CO)6
to afford 17 (70%). Next, a Pd-catalyzed intramolecular
aromatic amination20 was performed involving free NH and
aromatic bromide residue, which afforded a fused tricyclic 1,4-
oxazepane derivative, 18 (56%).
Scheme 4. (a) Relative Gibbs Free Energies (in kcal mol−1)
of the Four Isomers of 5aa Computed at COSMO(THF)-
ZORA-BLYP-D3(BJ)/TZ2P. (b) Plausible Mechanism for
Z−E Isomerization of Compound 5
Scheme 5. Study of [3 + 4]-Annulation of α-Halo
Hydroxamates and 1,4-Amphoteric Agenta
aReaction conditions: α-bromo hydroxamate 1 (2.0 equiv), hydroxyl
enones 7 (1.0 equiv), and Na2CO3 (3.0 equiv) in (CF3)2CHOH (0.2
M).
Scheme 6. Evaluation of Other Related 1,4-Amphoteric
Systems
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■ CONCLUSIONS
In summary, we have developed a new and efficient annulation
strategy to synthesize different saturated medium-ring nitrogen
heterocycles by employing azaoxyallyl cation and 1,3/1,4-
amphoteric compounds. Use of hydroxyl-alkynones resulted in
sterically less favored Z-exocyclic olefin in the product, which
was rationalized on the basis of involvement of HFIP in
stabilizing the corresponding transition state. DFT calculations
were also performed to corroborate with the experimental
results. A more challenging [3 + 4]-annulation using 1,4-
amphoteric compounds was also successfully demonstrated.
Overall, the present work showcases the use of different [1,m]-
amphoteric system as a new trapping modality of azaoxyallyl
cation, which is very distinct from the growing body of
literature on the azaoxyallyl cation and afforded a new strategy
for the preparation of saturated N-heterocycles.
■ EXPERIMENTAL SECTION
General Experimental Section. Unless otherwise noted, all the
reactions presented in the manuscript were performed maintaining an
inert atmosphere (i.e., under a positive pressure of nitrogen or argon)
and, oven or flame-dried glasswares was used. Dry solvents were used
in the study; either dried following the standard procedures or
obtained commercially and for tetrahydrofuran (THF), it was freshly
distilled before use. Solvent distillation was performed on heating
mantle, and oil baths were used for heating reactions performed in the
study. Unless otherwise mentioned, the reagents and catalysts used in
the study were purchased commercially and used without any
purification. Reaction monitoring was performed by thin layer
chromatography (TLC) analysis, and Merck silica gel 60 F 254
plates were used. Visualization of the TLC plates was made under UV
light (254 nm) or by using 10% ethanolic phosphomolybdic acid or
1% aqueous KMnO4 or iodine. Silica gel flash column chromatog-
raphy was performed by using silica gel of 230−400 mesh. 1H, 13C,
and 19F NMR spectra were recorded on AVANCE III, Bruker at 400,
100, and 376 MHz spectrometers, respectively, using CDCl3.
1H
NMR chemical shift are expressed in ppm (δ) relative to δ = 7.26 for
CDCl3.
13C{1H} NMR chemical shift is expressed in ppm (δ) relative
to δ = 77.16 for CDCl3 resonance. Fourier transform infrared (FT-IR)
experiments were performed on PerkinElmer Spectrum Version
10.03.08. HRMS and Electron spray ionization (ESI) (m/z) spectra
were recorded on Agilent Technologies 6530 Accurate-Mass Q-TOF
LC/MS.
The α-halo hydroxamate derivatives (1a−1f) are known com-
pounds and were prepared according to the literature method.9l,10f
Trans-hydroxyl enone derivatives (2a−2i) and compounds 4a and
4e−4f are known in the literature and were prepared according to the
reported method.21,22 We additionally prepared compound 4b−4d
using the similar procedure as reported for related compounds.
Among the linear trans-hydroxyenone derivatives, 7a−7e and 7g−7h
are the known compound and prepared according to the literature
method.23 Compound 7f was additionally prepared following the
similar method described for the preparation of related compounds.
4-Hydroxy-1-(4-methoxyphenyl)but-2-yn-1-one (4b). This com-
pound was prepared from the THP-protected alcohol (1.0 g, 3.65
mmol) in the presence of PPTS, following the same literature
procedure as described for related compounds.22 The final compound
was purified by silica gel column chromatography (2:3 EtOAC/
hexane) to obtain the product as the yellow solid 67% (0.46 g) yield;
1H NMR (400 MHz, CDCl3): δ 8.07 (d, J = 8.7 Hz, 2H), 6.90 (d, J =
8.7 Hz, 2H), 4.55 (s, 2H), 3.85 (s, 3H); 13C{1H} NMR (100 MHz,
CDCl3): δ 176.8, 164.8, 132.3, 129.6, 114.0, 92.3, 83.2, 55.7, 51.0;
HRMS (ESI-TOF) m/z: [M + Na]+ calcd for C11H10NaO3, 213.0528;
found, 213.0524.
1-(4-Chlorophenyl)-4-hydroxybut-2-yn-1-one (4c). Starting from
the THP-protected alcohol (0.7 g, 2.52 mmol), PPTS treatment in
refluxing ethanol afforded the free alcohol 4b as the yellow solid in
70% (0.34 g) yield; 1H NMR (400 MHz, CDCl3): δ 8.06 (d, J = 8.4
Hz, 2H), 7.46 (d, J = 8.4 Hz, 2H), 4.57 (s, 2H); 13C{1H} NMR (100
MHz, CDCl3): δ 176.5, 141.2, 134.8, 131.1, 129.2, 92.7, 83.2, 51.2;
HRMS (ESI-TOF) m/z: [M + Na]+ calcd for C10H7ClNaO2,
217.0032; found, 217.0027.
4-Hydroxy-1-(3-methoxyphenyl)but-2-yn-1-one (4d). This com-
pound was prepared similarly as compound 4b. Starting from the
corresponding THP-protected alcohol (0.8 g, 2.92 mmol), PPTS
treatment in refluxing ethanol afforded the free alcohol 4d as the
yellow solid in 65% (0.36 g) yield); 1H NMR (400 MHz, CDCl3): δ
7.67 (d, J = 7.4 Hz, 1H), 7.51 (s, 1H), 7.27 (dd, J = 11.7, 4.0 Hz, 1H),
7.07 (d, J = 7.7 Hz, 1H), 4.54 (s, 2H), 4.17 (s, 1H), 3.76 (s, 3H);
13C{1H} NMR (100 MHz, CDCl3): δ 177.8, 159.6, 137.4, 129.6,
122.9, 121.1, 112.8, 93.2, 82.9, 55.3, 50.6; HRMS (ESI-TOF) m/z:
[M + Na]+ calcd for C11H10NaO3, 213.0528; found, 213.0522.
(E)-1-(2-Bromophenyl)-5-hydroxypent-2-en-1-one (7f). This
compound was prepared following the same literature procedure as
described for related compounds23 and was obtained as the white
solid in 62% (0.43 g) yield from the corresponding TBS-protected
alcohol (1.0 g, 2.72 mmol); 1H NMR (400 MHz, CDCl3): δ 7.59 (d, J
= 7.9 Hz, 1H), 7.38−7.27 (m, 3H), 6.74−6.66 (m, 1H), 6.53 (d, J =
15.9 Hz, 1H), 3.78 (t, J = 6.2 Hz, 2H), 2.54 (q, J = 6.3 Hz, 2H);
13C{1H} NMR (100 MHz, CDCl3): δ 195.0, 148.8, 140.9, 133.5,
132.1, 131.4, 129.2, 127.4, 119.5, 60.9, 36.0; HRMS (ESI-TOF) m/z:
[M + Na]+ calcd for C11H11BrNaO2, 276.9840; found, 276.9836.
General Procedure for [3 + 3]-Annulation of α-Halo
Hydroxamates (Precursor to Azaoxyallyl Cation) and Hydrox-
yl Enone Derivatives (2) to Morpholin-3-ones, (3). To a solution
of α-bromo hydroxamate 1 (2.0 equiv) and hydroxyl enones 2 (1.0
equiv) in (CF3)2CHOH (0.2 M), was added Na2CO3 (3.0 equiv).
The reaction mixture was stirred at room temperature, and the
progress of the reaction was monitored by TLC. Upon completion of
the reaction (ca. 6−8 h), HFIP was removed under the reduced
pressure, and the crude was purified by silica gel column
chromatography (using ether−hexane mixture as eluent) to afford
the corresponding annulation products 3aa−3ai.
4-(Benzyloxy)-2,2-dimethyl-5-(2-oxo-2-phenylethyl)morpholin-
3-one (3aa). Following the general procedure, reaction between (E)-
4-hydroxy-1-phenylbut-2-en-1-one, 2a (0.10 g, 0.6 mmol, 1.0 equiv)
and α-bromo hydroxamate 1a (0.334 g, 1.2 mmol, 2.0 equiv) afforded
the corresponding morpholin-3-one 3aa, which was purified by silica
gel column chromatography (3:7 Et2O/hexane as eluent) to give the
title compound as the yellow solid in 95% (0.209 g) yield.
[Gram Scale synthesis]. 1a (3.36 g, 12.4 mmol, 2.0 equiv) and 2a
(1.0 g, 6.2 mmol, 1.0 equiv) were taken in 20 mL HFIP and was
added Na2CO3 (1.97 g, 18.6 mmol, 3.0 equiv). The reaction mixture
was stirred for 8 h at room temperature, and the solvent was removed
in vacuo. The title compound was isolated in 91% (1.98 g) yield,
following same chromatographic separation process as described
above. Rf 0.4 (2:3 Et2O/hexane); FT-IR (ν cm
−1): 2979, 2936, 1739,
1677, 1285, 1176; 1H NMR (400 MHz, CDCl3): δ 7.90−7.87 (m,
2H), 7.59−7.54 (m, 1H), 7.50 (d, J = 8.0 Hz, 2H), 7.43−7.40 (m,
2H), 7.36−7.34 (m, 3H), 5.02 (d, J = 10.2 Hz, 1H), 4.98 (d, J = 10.2
Hz, 1H), 4.12−4.09 (m, 1H), 4.00−3.96 (m, 1H), 3.75 (dd, J = 12.5,
Scheme 7. Follow-Up Studiesa
aReaction conditions: (a) H2, 10% Pd/C, MeOH, 20 h; (b) di-tert-
butyl azodicarboxylate, PPh3, DCM, 0 °C-rt, 16 h; (c) Mo(CO)6,
CH3CN−H2O (9:1), 120 °C, 12 h; (d) 5 mol % Pd(OAc)2, 50 mol %
Cu(OAc)2, K2CO3 (3.0 equiv), toluene, 110 °C, and 24 h.
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2.3 Hz, 1H), 3.50−3.44 (m, 1H) 3.34 (dd, J = 17.7, 9.4 Hz, 1H), 1.48
(s, 3H), 1.47 (s, 3H); 13C{1H} NMR (100 MHz, CDCl3): δ 197.7,
170.3, 136.4, 134.7, 133.7, 130.0, 129.1, 128.8, 128.6, 128.1, 78.7,
76.3, 62.2, 57.1, 38.0, 26.4, 23.9; HRMS (ESI-TOF) m/z: [M + Na]+
calcd for C21H23NNaO4, 376.1525; found, 376.1519.
4-(Benzyloxy)-2,2-dimethyl-5-(2-oxo-2-(p-tolyl)ethyl)morpholin-
3-one (3ab). Following the general procedure, reaction between (E)-
4-hydroxy-1-(p-tolyl)but-2-en-1-one 2b (0.05 g, 0.3 mmol, 1.0 equiv)
and α-bromo hydroxamate 1a (0.163 g, 0.6 mmol, 2.0 equiv) afforded
the corresponding morpholin-3-one 3ab, which was purified by silica
gel column chromatography (3:7 Et2O/hexane as eluent) to give the
title compound as colorless liquid in 81% (0.84 g) yield. Rf 0.36 (2:3
Et2O/hexane);
1H NMR (400 MHz, CDCl3): δ 7.71 (d, J = 8.2 Hz,
2H), 7.34−7.32 (m, 2H), 7.28−7.26 (m, 3H), 7.16 (d, J = 8.0 Hz,
2H), 4.94 (d, J = 10.2 Hz, 1H), 4.90 (d, J = 10.2 Hz, 1H), 4.04−4.00
(m, 1H), 3.89 (dd, J = 12.5, 2.2 Hz, 1H), 3.66 (dd, J = 12.5, 2.2 Hz,
1H), 3.36 (dd, J = 17.5, 2.2 Hz, 1H), 3.23 (dd, J = 17.6, 9.4 Hz, 1H),
2.32 (s, 3H), 1.40 (s, 3H), 1.39 (s, 3H); 13C{1H} NMR (100 MHz,
CDCl3): δ 197.3, 170.3, 144.5, 134.8, 134.0, 130.0, 129.4, 129.1,
128.6, 128.2, 78.7, 76.3, 62.3, 57.2, 37.8, 26.4, 23.9, 21.8; HRMS
(ESI-TOF) m/z: [M + Na]+ calcd for C22H25NNaO4, 390.1681;
found, 390.1675.
4-(Benzyloxy)-5-(2-(4-methoxyphenyl)-2-oxoethyl)-2,2-dimethyl-
morpholin-3-one (3ac). Following the general procedure, reaction
between (E)-4-hydroxy-1-(4-methoxyphenyl)but-2-en-1-one 2c (0.10
g, 0.5 mmol, 1.0 equiv) and α-bromo hydroxamate 1a (0.271 g, 1.0
mmol, 2.0 equiv) afforded the corresponding morpholin-3-one 3ac,
which was purified by silica gel column chromatography (2:3 Et2O/
hexane as eluent) to give the title compound as colorless liquid in 91%
(0.182 g) yield. Rf 0.3 (2:3 Et2O/hexane);
1H NMR (400 MHz,
CDCl3): δ 7.86 (d, J = 8.9 Hz, 2H), 7.42−7.39 (m, 2H), 7.34−7.33
(m, 3H), 6.89 (d, J = 8.9 Hz, 2H), 5.01 (d, J = 10.2 Hz, 1H), 4.97 (d,
J = 10.1 Hz, 1H), 4.11−4.08 (m, 1H), 3.96 (dd, J = 12.5, 2.1 Hz, 1H),
3.84 (s, 3H), 3.74 (dd, J = 12.5, 2.2 Hz, 1H), 3.41 (dd, J = 17.4, 2.2
Hz, 1H), 3.28 (dd, J = 17.4, 9.4 Hz, 1H), 1.47 (s, 3H), 1.45 (s, 3H);
13C{1H} NMR (100 MHz, CDCl3): δ 196.1, 170.3, 163.9, 134.7,
130.4, 129.9, 129.5, 129.0, 128.6, 113.9, 78.6, 76.3, 62.2, 57.2, 55.5,
37.5, 26.4, 23.9; HRMS (ESI-TOF) m/z: [M + Na]+calcd for
C22H25NNaO5, 406.1630; found, 406.1626.
4-(Benzyloxy)-5-(2-(4-fluorophenyl)-2-oxoethyl)-2,2-dimethyl-
morpholin-3-one (3ad). Following the general procedure, reaction
between (E)-1-(4-fluorophenyl)-4-hydroxybut-2-en-1-one 2d (0.10 g,
0.6 mmol, 1.0 equiv) and α-bromo hydroxamate 1a (0.301 g, 1.2
mmol, 2.0 equiv) afforded the corresponding morpholin-3-one 3ad,
which was purified by silica gel column chromatography (3:7 Et2O/
hexane as eluent) to give the title compound as colorless liquid in 90%
(0.186 g) yield. Rf 0.35 (2:3 Et2O/hexane);
1H NMR (400 MHz,
CDCl3): δ 7.91 (dd, J = 8.6, 5.5 Hz, 2H), 7.41−7.40 (m, 2H),7.36−
7.35 (m, 3H), 7.11 (t, J = 8.5 Hz, 2H), 5.02 (d, J = 10.2 Hz, 1H), 4.97
(d, J = 10.2 Hz, 1H), 4.10−4.07 (m, 1H), 3.73 (dd, J = 12.5, 1.9 Hz,
1H), 3.73 (dd, J = 12.5, 1.9 Hz, 1H), 3.43 (dd, J = 17.5, 2.4 Hz, 1H),
3.29 (dd, J = 17.6, 9.3 Hz, 1H), 1.48 (s, 3H), 1.47 (s, 3H); 13C{1H}
NMR (100 MHz, CDCl3): δ 196.2, 170.4, 166.1 (d, J = 254.2
Hz),134.8, 133.0 (d, J = 3.0 Hz), 130.9 (d, J = 9.4 Hz), 130.0, 129.2,
128.7, 116.0 (d, J = 21.8 Hz), 78.8, 76.4, 62.3, 57.2, 38.0, 26.4, 24.0;
HRMS (ESI-TOF) m/z: [M + Na]+ calcd for C21H22FNNaO4,
394.1431; found, 394.1427.
4-(Benzyloxy)-5-(2-(4-bromophenyl)-2-oxoethyl)-2,2-dimethyl-
morpholin-3-one (3ae). Following the general procedure, reaction
between (E)-1-(4-bromophenyl)-4-hydroxybut-2-en-1-one 2e (0.10 g,
0.4 mmol, 1.0 equiv) and α-bromo hydroxamate 1a (0.217 g, 0.8
mmol, 2.0 equiv) afforded the corresponding morpholin-3-one 3ae,
which was purified by silica gel column chromatography (3:7 Et2O/
hexane as eluent) to give the title compound as the white solid in 87%
(0.156 g) yield. Rf 0.36 (2:3 Et2O/hexane); mp 103.4−105.0 °C; 1H
NMR (400 MHz, CDCl3): δ 7.73 (d, J = 8.3 Hz, 2H), 7.57 (d, J = 8.3
Hz, 2H), 7.40−7.36 (m, 5H), 5.01 (d, J = 10.2 Hz, 1H), 4.96 (d, J =
10.2 Hz, 1H), 4.08−4.06 (m, 1H), 3.97 (d, J = 12.3 Hz, 1H), 3.72 (d,
J = 12.4 Hz, 1H), 3.40 (d, J = 15.7 Hz, 1H), 3.26 (dd, J = 17.7, 9.2
Hz, 1H), 1.47 (s, 3H), 1.46 (s, 3H); 13C{1H} NMR (100 MHz,
CDCl3): δ 196.7, 170.3, 135.2, 134.7, 132.1, 130.0, 129.6, 129.2,
128.9, 128.7, 78.8, 76.4, 62.2, 57.2, 38.0, 26.4, 24.0; HRMS (ESI-
TOF) m/z: [M + Na]+ calcd for C21H22BrNNaO4, 454.0630; found,
454.0623.
4-(Benzyloxy)-5-(2-(3-methoxyphenyl)-2-oxoethyl)-2,2-dimethyl-
morpholin-3-one (3af). Following the general procedure, reaction
between (E)-4-hydroxy-1-(3-methoxyphenyl)but-2-en-1-one 2af
(0.10 g, 0.5 mmol, 1.0 equiv) and α-bromo hydroxamate 1a (0.271
g, 1.0 mmol, 2.0 equiv) afforded the corresponding morpholin-3-one
3af, which was purified by silica gel column chromatography (2:3
Et2O/hexane as the eluent) to give the title compound as yellow
liquid in 89% (0.186 g) yield. Rf 0.3 (2:3 Et2O/hexane);
1H NMR
(400 MHz, CDCl3): δ 7.45−7.38 (m, 4H), 7.33−7.29 (m, 4H), 7.08
(d, J = 7.0 Hz, 1H), 4.99 (d, J = 10.2 Hz, 1H), 4.96 (d, J = 10.2 Hz,
1H), 4.09−4.06 (m, 1H), 3.95 (d, J = 11.1 Hz, 1H), 3.79 (s, 3H),
3.72 (d, J = 13.8 Hz, 1H), 3.43 (d, J = 15.8 Hz, 1H), 3.29 (dd, J =
17.6, 9.3 Hz, 1H), 1.46 (s, 3H), 1.45 (s, 3H); 13C{1H} NMR (100
MHz, CDCl3): δ 197.4, 170.2, 159.8, 137.7, 134.6, 129.8, 129.6,
129.0, 128.5, 120.7, 120.0, 112.1, 78.6, 76.2, 62.1, 57.1, 55.4, 38.0,
26.3, 23.8; HRMS (ESI-TOF) m/z: [M + Na]+ calcd for
C22H25NNaO5, 406.1630; found, 406.1627.
4-(Benzyloxy)-2,2-dimethyl-5-(2-oxo-2-(o-tolyl)ethyl)morpholin-
3-one (3ag). Following the general procedure, reaction between (E)-
4-hydroxy-1-(o-tolyl)but-2-en-1-one 2g (0.10 g, 0.6 mmol, 1.0 equiv)
and α-bromo hydroxamate 1a (0.325 g, 1.2 mmol, 2.0 equiv) afforded
the corresponding morpholin-3-one 3ag, which was purified by silica
gel column chromatography (3:7 Et2O/hexane as eluent) to give the
title compound as yellow liquid in 84% (0.175 g) yield. Rf 0.35 (2:3
Et2O/hexane);
1H NMR (400 MHz, CDCl3): δ 7.50 (d, J = 7.7 Hz,
1H), 7.30−7.28 (m, 2H), 7.24−7.23 (m, 4H), 7.12 (app t, J = 8.1 Hz,
2H), 4.88 (s, 2H), 3.98−3.95 (m, 1H), 3.85 (dd, J = 12.4, 2.7 Hz,
1H), 3.62 (dd, J = 12.5, 2.0 Hz, 1H), 3.30 (dd, J = 17.6, 3.2 Hz, 1H),
3.14 (dd, J = 17.6, 9.2 Hz, 1H), 2.35 (s, 3H), 1.35 (s, 3H), 1.35 (s,
3H); 13C{1H} NMR (100 MHz, CDCl3): δ 201.2, 170.3, 138.7,
136.8, 134.8, 132.2, 132.0, 129.9, 129.1, 129(2), 128.6, 125.9, 78.7,
76.4, 62.4, 57.3, 40.7, 26.4, 24.0, 21.6; HRMS (ESI-TOF) m/z: [M +
Na]+ calcd for C22H25NNaO4, 390.1681; found, 390.1677.
4-(Benzyloxy)-2,2-dimethyl-5-(2-(naphthalen-2-yl)-2-oxoethyl)-
morpholin-3-one (3ah). Following the general procedure, reaction
between (E)-4-hydroxy-1-(naphthalen-2-yl)but-2-en-1-one 2h (0.10
g, 0.5 mmol, 1.0 equiv) and α-bromo hydroxamate 1a (0.271 g, 1.0
mmol, 2.0 equiv) afforded the corresponding morpholin-3-one 3ah,
which was purified by silica gel column chromatography (3:7 Et2O/
hexane as eluent) to give the title compound as colorless liquid in 88%
(0.169 g) yield. Rf 0.4 (2:3 Et2O/hexane);
1H NMR (400 MHz,
CDCl3): δ 8.41 (s, 1H), 7.95 (app t, J = 7.4 Hz, 2H), 7.88 (dd, J =
8.4, 3.2 Hz, 2H), 7.62 (t, J = 7.4 Hz, 1H), 7.56 (t, J = 7.4 Hz, 1H),
7.46−7.42 (m, 2 H), 7.37−7.35 (m, 3H), 5.06 (d, J = 10.3 Hz, 1H),
5.01 (d, J = 10.2 Hz, 1H), 4.18−4.15 (m, 1H), 4.02 (dd, J = 12.3, 2.5
Hz, 1H), 3.81 (dd, J = 12.5, 1.9 Hz, 1H), 3.62 (dd, J = 17.5, 2.6 Hz,
1H), 3.47 (dd, J = 17.6, 9.4 Hz, 1H), 1.52 (s, 3H), 1.49 (s, 3H);
13C{1H} NMR (100 MHz, CDCl3): δ 197.7, 170.5, 135.9, 134.8,
133.8, 132.6, 130.2, 130.0, 129.8, 129.2, 128.9, 128.7, 127.9, 127.1,
123.6, 78.8, 76.5, 62.4, 57.4, 38.1, 26.5, 24.0; HRMS (ESI-TOF) m/z:
[M + Na]+ calcd for C25H25NNaO4, 426.1681; found, 426.1678.
4-Methoxy-2,2-dimethyl-5-(2-(naphthalen-2-yl)-2-oxoethyl)-
morpholin-3-one (3bh). Following the general procedure, reaction
between (E)-4-hydroxy-1-(naphthalen-2-yl)but-2-en-1-one 2h (0.10
g, 0.5 mmol, 1.0 equiv) and α-bromo hydroxamate 1b (0.271 g, 1.0
mmol, 2.0 equiv) afforded the corresponding morpholin-3-one 3bh,
which was purified by silica gel column chromatography (3:7 Et2O/
hexane as the eluent) to give the title compound as the white solid in
91% (0.139 g) yield. Rf 0.37 (2:3 Et2O/hexane); mp 102.1−103.5 °C;
1H NMR (400 MHz, CDCl3): δ 8.44 (s, 1H), 7.95 (dd, J = 17.2, 8.3
Hz, 2H), 7.86 (app t, J = 8.3 Hz, 2H), 7.59 (app t, J = 7.4 Hz, 1H),
7.53 (app t, J = 7.4 Hz, 1H), 4.47−4.44 (m, 1H), 4.15 (dd, J = 12.5,
2.9 Hz, 1H), 3.90 (dd, J = 12.5, 2.2 Hz, 1H), 3.78 (s, 3H), 3.67 (dd, J
= 17.6, 2.9 Hz, 1H), 3.52 (dd, J = 17.6, 9.2 Hz, 1H), 1.49 (s, 3H),
1.48 (s, 3H); 13C{1H} NMR (100 MHz, CDCl3): δ 197.6, 169.8,
135.8, 133.7, 132.5, 130.0, 129.7, 128.8, 128.7, 127.8, 127.0, 123.5,
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78.6, 62.5, 61.7, 55.7, 38.1, 26.3, 23.9; HRMS (ESI-TOF) m/z: [M +
Na]+ calcd for C19H21NNaO4, 350.1368; found, 350.1364.
4-(Benzyloxy)-3-(2-(naphthalen-2-yl)-2-oxoethyl)-1-oxa-4-
azaspiro[5.5]undecan-5-one (3ch). Following the general procedure,
reaction between (E)-4-hydroxy-1-(naphthalen-2-yl)but-2-en-1-one
2h (0.10 g, 0.5 mmol, 1.0 equiv) and α-bromo hydroxamate 1c
(0.311 g, 1.0 mmol, 2.0 equiv) afforded the corresponding morpholin-
3-one 3ch, which was purified by silica gel column chromatography
(1:3 Et2O/hexane as the eluent) to give the title compound as
colorless liquid in 84% (0.175 g) yield. Rf 0.45 (2:3 Et2O/hexane);
1H
NMR (400 MHz, CDCl3): δ 8.40 (s, 1H), 7.95 (app t, J = 7.3 Hz,
2H), 7.88 (d, J = 10.0 Hz, 2H), 7.61 (app t, J = 7.4 Hz, 1H), 7.58−
7.52 (m, 1H), 7.42−7.41 (m, 2H), 7.36−7.35 (m, 3H), 5.04 (d, J =
10.2 Hz, 1H), 4.99 (d, J = 10.2 Hz, 1H), 4.14−4.11 (m, 1H), 3.97
(dd, J = 12.3, 2.2 Hz, 1H), 3.82 (dd, J = 12.4, 1.3 Hz, 1H), 3.60 (dd, J
= 17.3, 2.0 Hz, 1H), 3.46 (dd, J = 17.6, 9.4 Hz, 1H), 2.05−1.98 (m,
2H), 1.82−1.78 (m, 2H), 1.55−1.43 (m, 4H), 1.34−1.26 (m, 2H);
13C{1H} NMR (100 MHz, CDCl3): δ 197.8, 170.8, 135.9, 134.9,
133.9, 132.6, 130.2, 130.1, 129.7, 129.2, 128.9, 128.7, 127.9, 127.1,
123.6, 79.8, 76.4, 61.8, 57.2, 38.3, 33.8, 30.2, 25.2, 20.9, 20.7; HRMS
(ESI-TOF) m/z: [M + Na]+ calcd for C28H29NNaO4, 466.1994;
found, 466.1989.
4-(Benzyloxy)-2,2-dimethyl-5-(2-oxo-4-phenylbutyl)morpholin-
3-one (3ai). Following the general procedure, reaction between
following the general procedure, reaction between (E)-6-hydroxy-1-
phenylhex-4-en-3-one 2i (0.10 g, 0.5 mmol, 1.0 equiv) and α-bromo
hydroxamate 1a (0.271 g, 1.0 mmol, 2.0 equiv) afforded the
corresponding morpholin-3-one 3ai, which was purified by silica gel
column chromatography (3:7 Et2O/hexane as the eluent) to give the
title compound as the white solid in 69% (0.138 g) yield. Rf 0.4 (2:3
Et2O/hexane);
1H NMR (400 MHz, CDCl3): δ 7.38−7.36 (m, 2H),
7.32−7.31 (m, 3H), 7.21 (app t, J = 7.5 Hz, 2H), 7.13 (app t, J = 7.1
Hz, 1H), 7.05 (d, J = 7.5 Hz, 2H), 4.90 (d, J = 9.8 Hz, 1H), 4.85 (d, J
= 9.9 Hz, 1H), 3.99−3.95 (m, 1H), 3.83 (dd, J = 12.4, 3.2 Hz, 1H),
3.56 (dd, J = 12.4, 3.0 Hz, 1H), 2.83−2.71 (m, 3H), 2.68−2.58 (m,
3H), 1.39 (s, 6H); 13C{1H} NMR (100 MHz, CDCl3): δ 207.5,
170.0, 140.6, 134.6, 130.0, 129.1, 128.6, 128.6(2), 128.3, 126.3, 78.7,
76.2, 62.4, 56.5, 44.9, 42.3, 29.5, 25.9, 24.2; HRMS (ESI-TOF) m/z:
[M + Na]+ calcd for C23H27NNaO4, 404.1838; found, 404.1834.
General Procedure for [3 + 3]-Annulation of α-Halo
Hydroxamates (Precursor to Azaoxyallyl Cation) and Hydrox-
yl Alkynone Derivatives (4) to Morpholin-3-one Derivatives,
5. To a solution of α-bromo hydroxamate 1 (2.0 equiv) and hydroxyl
alkynones 4 (1.0 equiv) in (CF3)2CHOH (0.2 M), was added
Na2CO3 (3.0 equiv). The reaction mixture was stirred at room
temperature, and the reaction progress was monitored by TLC. Upon
completion of the reaction (ca. 5−6 h), HFIP was removed under
reduced pressure, and the crude was purified by silica gel column
chromatography (using ether−hexane mixture as the eluent) to afford
the corresponding annulated products, 5aa−5ae.
(Z)-4-(Benzyloxy)-2,2-dimethyl-5-(2-oxo-2-phenylethylidene)-
morpholin-3-one (5aa). Following the general procedure, reaction
between 4-hydroxy-1-phenylbut-2-yn-1-one 4a (0.05 g, 0.3 mmol, 1.0
equiv) and α-bromo hydroxamate 1a (0.163 g, 0.6 mmol, 2.0 equiv)
afforded the corresponding (Z)-4-(benzyloxy)-morpholin-3-one 5aa,
which was purified by silica gel column chromatography (3:7 Et2O/
hexane as the eluent) to give the title compound as colorless liquid in
68% (0.075 g) yield. Rf 0.4 (2:3 Et2O/hexane);
1H NMR (400 MHz,
CDCl3): δ 7.77 (d, J = 7.5 Hz, 2H), 7.43 (t, J = 7.3 Hz, 1H), 7.31
(app t, J = 7.6 Hz, 2H), 7.26−7.19 (m, 5H), 5.29 (s, 1H), 4.84 (s,
2H), 4.44 (s, 2H), 1.50 (s, 6H); 13C{1H} NMR (100 MHz, CDCl3):
δ 193.2, 168.2, 137.4, 136.8, 133.2, 133.2(2), 130.2, 129.2, 129.0,
128.5, 128.2, 102.0, 78.9, 76.6, 62.5, 24.6; HRMS (ESI-TOF) m/z:
[M + Na]+ calcd for C21H21NNaO4, 374.1368; found, 374.1364.
(Z)-4-(Benzyloxy)-5-(2-(4-methoxyphenyl)-2-oxoethylidene)-2,2-
dimethylmorpholin-3-one (5ab). Following the general procedure,
reaction between 4-hydroxy-1-(4-methoxyphenyl)but-2-yn-1-one 4b
(0.05 g, 0.3 mmol, 1.0 equiv) and α-bromo hydroxamate 1a (0.163 g,
0.6 mmol, 2.0 equiv) afforded the corresponding (Z)-4-(benzyloxy)-
morpholin-3-one 5ab, which was purified by silica gel column
chromatography (2:3 Et2O/hexane as the eluent) to give the title
compound as yellow liquid in 70% (0.070 g) yield. Rf 0.3 (2:3 Et2O/
hexane); 1H NMR (400 MHz, CDCl3): δ 7.78 (d, J = 8.5 Hz, 2H),
7.30−7.25 (m, 5H), 6.81 (d, J = 8.4 Hz, 2H), 5.29 (s, 1H), 4.86 (s,
2H), 4.45 (s, 2H), 3.82 (s, 3H), 1.55 (s, 6H); 13C{1H} NMR (100
MHz, CDCl3): δ 192.0, 168.2, 163.7, 136.2, 133.3, 131.6, 130.6,
130.3, 128.9, 128.2, 113.8, 102.5, 78.9, 76.6, 62.6, 55.6, 24.7; HRMS
(ESI-TOF) m/z: [M + Na]+ calcd for C22H23NNaO5, 404.1474;
found, 404.1467.
(Z)-4-Methoxy-5-(2-(4-methoxyphenyl)-2-oxoethylidene)-2,2-di-
methylmorpholin-3-one (5bb). Following the general procedure,
reaction between 4-hydroxy-1-(4-methoxyphenyl)but-2-yn-1-one 4b
(0.05 g, 0.3 mmol, 1.0 equiv) and α-bromo hydroxamate 1b (0.118 g,
0.6 mmol, 2.0 equiv) afforded the corresponding (Z)-4-methoxy-
morpholin-3-one 5bb, which was purified by silica gel column
chromatography (2:3 Et2O/hexane as eluent) to give the title
compound as yellow liquid in 64% (0.051 g) yield. Rf 0.3 (2:3 Et2O/
hexane); 1H NMR (400 MHz, CD2Cl2): δ 7.91 (d, J = 8.8 Hz, 2H),
6.95 (d, J = 8.8 Hz, 2H), 5.28 (s, 1H), 4.47 (s, 2H), 3.86 (s, 3H), 3.50
(s, 3H), 1.48 (s, 6H); 13C{1H} NMR (100 MHz, CD2Cl2): δ 192.0,
168.2, 164.2, 136.3, 131.6, 131.3, 114.3, 102.3, 79.1, 62.9, 62.8, 56.1,
24.8; HRMS (ESI-TOF) m/z: [M + Na]+ calcd for C16H19NNaO5,
328.1161; found, 328.1154.
(Z)-4-Methoxy-3-(2-(4-methoxyphenyl)-2-oxoethylidene)-1-oxa-
4-azaspiro[5.5]undecan-5-one (5cb). Following the general proce-
dure, reaction between 4-hydroxy-1-(4-methoxyphenyl)but-2-yn-1-
one 4b (0.05 g, 0.3 mmol, 1.0 equiv) and α-bromo hydroxamate 1c
(0.187 g, 0.6 mmol, 2.0 equiv) afforded the corresponding (Z)-4-
methoxy-morpholin-3-one 5cb, which was purified by silica gel
column chromatography (3:7 Et2O/hexane as eluent) to give the title
compound as yellow liquid in 58% (0.064 g) yield. Rf 0.42 (2:3 Et2O/
hexane); FT-IR (ν cm−1): 2932, 1697, 1663, 1598, 1309, 1249, 1166,
1026; 1H NMR (400 MHz, CDCl3): δ 7.80 (d, J = 8.7 Hz, 2H),
7.31−7.29 (m, 2H), 7.29−7.28 (m, 3H), 6.83 (d, J = 8.8 Hz, 2H),
5.30 (s, 1H), 4.87 (s, 2H), 4.48 (s, 2H), 3.84 (s, 3H), 2.00−1.97 (m,
2H), 1.92−1.85 (m, 2H), 1.74−1.61 (m, 4H), 1.37−1.29 (m, 2H);
13C{1H} NMR (100 MHz, CDCl3): δ 192.1, 168.4, 163.7, 136.2,
133.4, 131.5, 130.7, 130.3, 128.9, 128.2, 113.8, 102.1, 79.9, 76.6, 62.1,
55.6, 31.5, 25.1, 20.7; HRMS (ESI-TOF) m/z: [M + Na]+ calcd for
C25H27NNaO5, 444.1787; found, 444.1781.
(Z)-4-(Benzyloxy)-5-(2-(4-chlorophenyl)-2-oxoethylidene)-2,2-di-
methylmorpholin-3-one (5ac). Following the general procedure,
reaction between 1-(4-chlorophenyl)-4-hydroxybut-2-yn-1-one 4c
(0.05 g, 0.25 mmol, 1.0 equiv) and α-bromo hydroxamate 1a
(0.136 g, 0.5 mmol, 2.0 equiv) afforded the corresponding (Z)-4-
(benzyloxy)-morpholin-3-one 5ac, which was purified by silica gel
column chromatography (3:7 Et2O/hexane as the eluent) to give the
title compound as yellow liquid in 67% (0.066 g) yield. Rf 0.4 (2:3
Et2O/hexane);
1H NMR (400 MHz, CDCl3): δ 7.67 (d, J = 8.5 Hz,
2H), 7.27−7.25 (m, 7H), 5.24 (s, 1H), 4.84 (s, 2H), 4.45 (s, 2H),
1.51 (s, 6H); 13C{1H} NMR (100 MHz, CDCl3): δ 192.1, 168.2,
139.6, 137.3, 135.9, 133.1, 130.5, 130.2, 129.1, 128.8, 128.3, 101.3,
79.0, 76.7, 62.5, 24.6; HRMS (ESI-TOF) m/z: [M + Na]+ calcd for
C21H20ClNNaO4, 408.0979; found, 408.0954.
(Z)-4-(Benzyloxy)-5-(2-(3-methoxyphenyl)-2-oxoethylidene)-2,2-
dimethylmorpholin-3-one (5ad). Following the general procedure,
reaction between 4-hydroxy-1-(3-methoxyphenyl)but-2-yn-1-one 4d
(0.05 g, 0.3 mmol, 1.0 equiv) and α-bromo hydroxamate 1a (0.163 g,
0.6 mmol, 2.0 equiv) afforded the corresponding (Z)-4-(benzyloxy)-
morpholin-3-one 5ad, which was purified by silica gel column
chromatography (2:3 Et2O/hexane as the eluent) to give the title
compound as yellow liquid in 65% (0.065 g) yield. Rf 0.3 (2:3 Et2O/
hexane); 1H NMR (400 MHz, CDCl3): δ 7.39 (d, J = 7.5 Hz, 2H),
7.28−7.22 (m, 6H), 6.99 (dd, J = 8.2, 1.9 Hz, 1H), 5.29 (s, 1H), 4.83
(s, 2H), 4.44 (s, 2H), 3.70 (s, 3H), 1.50 (s, 6H); 13C{1H} NMR (100
MHz, CDCl3): δ 193.0, 168.2, 159.8, 138.9, 136.8, 133.3, 130.2,
129.5, 128.9, 128.2, 122.4, 120.2, 112.5, 102.1, 78.9, 76.6, 62.5, 55.4,
24.7; HRMS (ESI-TOF) m/z: [M + Na]+ calcd for C22H23NNaO5,
404.1474; found, 404.1468.
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(Z)-4-(Benzyloxy)-2,2-dimethyl-5-(2-oxo-4-phenylbutylidene)-
morpholin-3-one (5ae). Following the general procedure, reaction
between 6-hydroxy-1-phenylhex-4-yn-3-one 4e (0.05 g, 0.26 mmol,
1.0 equiv) and α-bromo hydroxamate 1a (0.141 g, 0.52 mmol, 2.0
equiv) afforded the corresponding (Z)-4-(benzyloxy)-morpholin-3-
one 5ae, which was purified by silica gel column chromatography (3:7
Et2O/hexane as the eluent) to give the title compound as yellow
liquid in 62% (0.062 g) yield. Rf 0.35 (2:3 Et2O/hexane);
1H NMR
(400 MHz, CDCl3): δ 7.37−7.36 (m, 2H), 7.32−7.31 (m, 4H),
7.24−7.18 (m, 2H), 7.10 (d, J = 7.7 Hz, 2H), 5.89 (s, 1H), 4.97 (s,
2H), 4.88 (s, 2H), 2.82 (t, J = 7.6 Hz, 2H), 2.68 (t, J = 7.6 Hz, 2H),
1.41 (s, 6H); 13C{1H} NMR (100 MHz, CDCl3): δ 199.2, 168.8,
150.1, 141.2, 133.6, 130.0, 129.6, 128.8, 128.6, 128.5, 126.3, 100.3,
77.5, 77.3, 60.8, 46.1, 30.6, 23.7; HRMS (ESI-TOF) m/z: [M + Na]+
calcd for C23H25NNaO4, 402.1681; found, 402.1672.
4-(Benzyloxy)-5-((3-(benzyloxy)-2,5,5-trimethyl-4-oxooxazolidin-
2-yl)methylene)-2,2-dimethylmorpholin-3-one (6). Following the
general procedure, reaction between 5-hydroxypent-3-yn-2-one 4f
(0.05 g, 0.5 mmol, 1.0 equiv) and α-bromo hydroxamate 1a (0.136 g,
0.5 mmol, 1.0 equiv) afforded the corresponding (Z)-4-(benzyloxy)-
morpholin-3-one 6, which was purified by silica gel column
chromatography (3:7 Et2O/hexane as the eluent) to give the title
compound as the white solid in 59% (0.144 g) yield. Rf 0.35 (2:3
Et2O/hexane); mp 122.8−124.0 °C; FT-IR (ν cm−1): 3304, 2982,
2935, 1730, 1692, 1661, 1456, 1320, 1201, 1071; 1H NMR (400
MHz, CDCl3): δ 7.46−7.44 (m, 2H), 7.41−7.39 (m, 3H), 7.37−7.30
(m, 3H), 7.26−7.22 (m, 2H), 5.58 (s, 1H), 5.15 (d, J = 10.0 Hz, 1H),
5.07 (d, J = 10.0 Hz, 1H), 4.93 (s, 2H), 4.67 (d, J = 15.2 Hz, 1H),
4.61 (d, J = 15.2 Hz, 1H), 1.49 (s, 3H), 1.47 (s, 3H), 1.43 (s, 3H),
1.42 (s, 3H), 1.30 (s, 3H); 13C{1H} NMR (100 MHz, CDCl3): δ
171.7, 167.9, 135.3, 134.6, 133.7, 130.3, 129.8, 129.3, 129.3(2), 128.7,
128.7(2), 104.1, 91.4, 79.2, 78.2, 77.6, 76.5, 58.4, 28.2, 26.6, 24.9,
24.7, 23.8; HRMS (ESI-TOF) m/z: [M + Na]+ calcd for
C27H32N2NaO6, 503.2158; found, 503.2142.
Procedure for (Z)-5 to (E)-5 Isomerization.
(a) In CDCl3: Compounds (Z)-5ab/(Z)-5bb (20 mg) were
dissolved in the CDCl3 (0.5 mL) in the NMR tube and was
kept on standing for 24 h at room temperature. The sample
was analyzed by NMR spectroscopy. A quantitative conversion
was observed by NMR analysis.
(b) With p-TsOH: compound (Z)-5ab (40 mg, 0.1 mmol) was
dissolved in dry DCM (1.0 mL) and was added p-TsOH (0.1
equiv). The reaction mixture was stirred for 30 min at room
temperature, and the solvent was removed in vacuo. The crude
product was analyzed by NMR spectroscopy, and quantitative
conversion of (Z)-5ab to (E)-5ab was observed.
(E)-4-(Benzyloxy)-5-(2-(4-methoxyphenyl)-2-oxoethylidene)-2,2-
dimethylmorpholin-3-one (E-5ab). 1H NMR (400 MHz, CDCl3): δ
7.81 (d, J = 8.8 Hz, 2H), 7.53−7.51 (m, 2H), 7.44−7.41 (m, 3H),
6.92 (d, J = 8.8 Hz, 2H), 6.71 (s, 1H), 5.18 (s, 2H), 5.07 (s, 2H), 3.88
(s, 3H), 1.53 (s, 6H); 13C{1H} NMR (100 MHz, CDCl3): δ 188.9,
168.7, 163.3, 151.0, 133.8, 132.1, 130.3, 130.1, 129.6, 129.0, 113.9,
98.0, 77.6, 77.4, 61.1, 55.6, 23.8; HRMS (ESI-TOF) m/z: [M + Na]+
calcd for C22H23NNaO5, 404.1474; found, 404.1467.
(E)-4-Methoxy-5-(2-(4-methoxyphenyl)-2-oxoethylidene)-2,2-di-
methylmorpholin-3-one (E-5bb). 1H NMR (400 MHz, CDCl3): δ
7.92 (d, J = 8.6 Hz, 2H), 6.96 (d, J = 8.7 Hz, 2H), 6.71 (s, 1H), 5.21
(s, 2H), 3.92 (s, 3H), 3.88 (s, 3H), 1.52 (s, 6H); 13C{1H} NMR (100
MHz, CDCl3): δ 189.1, 168.2, 163.4, 150.3, 132.1, 130.4, 113.9, 97.3,
77.4, 62.6, 61.1, 55.6, 23.7; HRMS (ESI-TOF) m/z: [M + Na]+ calcd
for C16H19NNaO5, 328.1161; found, 328.1154.
(Z)-5-(2-(4-Methoxyphenyl)-2-oxoethylidene)-2,2-dimethylmor-
pholin-3-one (5ab′). To a solution of (E)-/(Z)-5ab (0.100 g, 0.26
mmol, 1.0 equiv) in acetonitrile/water (9:1, 2 mL), Mo(CO)6 (0.083
g, 0.30 mmol, 1.2 equiv) was added, and the reaction was stirred at
120 °C under argon for 12 h. After cooling to room temperature, the
mixture was then filtered through Celite and thoroughly washed with
ethyl acetate. Then, the filtrate was concentrated under vacuo, and the
resulting residue was purified by silica gel column chromatography
(3:7 EtOAc/hexane) to afford (Z)-5ab′ as the white solid in 74%
(0.053 g) and 76% (0.055 g) yields. Rf 0.3 (3:7 EtOAc/hexane); mp
124.5−125.5 °C; 1H NMR (400 MHz, CDCl3): δ 11.82 (s, 1H), 7.89
(d, J = 8.8 Hz, 2H), 6.93 (d, J = 8.8 Hz, 2H), 5.93 (s, 1H), 4.48 (s,
2H), 3.87 (s, 3H), 1.52 (s, 6H); 13C{1H} NMR (100 MHz, CDCl3)
190.1, 172.2, 163.5, 151.4, 131.3, 130.1, 114.0, 94.0, 77.1, 60.3, 55.6,
23.9; HRMS (ESI-TOF) m/z: [M + Na]+ calcd for C15H17NNaO4,
298.1055; found, 298.1047.
General Procedure for [3 + 4]-Annulation of α-Halo
Hydroxamates (Precursor to Azaoxyallyl Cation) and Hydrox-
yl Enone Derivatives (7) to 1,4-Oxazepan-3-ones, 8. To a
solution of α-bromo hydroxamate 1 (2.0 equiv) and hydroxyl enones
7 (1.0 equiv) in (CF3)2CHOH (0.2 M), was added Na2CO3 (3.0
equiv). The reaction mixture was stirred at 50 °C overnight, and the
reaction progress was monitored by TLC. Upon completion of the
reaction, HFIP was removed under reduced pressure, and the crude
was purified by silica gel column chromatography (using ether−
hexane mixture as the eluent) to afford the corresponding cyclic
products, 8aa−8bh.
4-(Benzyloxy)-2,2-dimethyl-5-(2-oxo-2-phenylethyl)-1,4-oxaze-
pan-3-one (8aa). Following the general procedure, reaction between
(E)-5-hydroxy-1-phenylpent-2-en-1-one 7a (0.10 g, 0.6 mmol, 1.0
equiv) and α-bromo hydroxamate 1a (0.325 g, 1.2 mmol, 2.0 equiv)
afforded the corresponding 1,4-oxazepan-3-one 8aa, which was
purified by silica gel column chromatography (3:7 Et2O/hexane as
the eluent) to give the title compound as the yellowish solid in 67%
(0.140 g) yield. Rf 0.4 (2:3 Et2O/hexane); mp 79.5−80.5 °C; 1H
NMR (400 MHz, CDCl3): δ 7.86 (d, J = 8.0 Hz, 2H), 7.57 (app t, J =
7.3 Hz, 1H), 7.45 (t, J = 7.6 Hz, 2H), 7.38−7.37 (m, 2H), 7.34−7.30
(m, 3H), 4.89 (d, J = 10.4 Hz, 1H), 4.83 (d, J = 10.4 Hz, 1H), 4.54−
4.48 (m, 1H), 3.84−3.78 (m, 1H), 3.67−3.60 (m, 1H), 3.40 (dd, J =
17.8, 8.8 Hz, 1H), 3.19 (dd, J = 17.8, 4.8 Hz, 1H), 2.15−2.08 (m,
2H), 1.55 (s, 3H), 1.53 (s, 3H); 13C{1H} NMR (100 MHz, CDCl3):
δ 197.9, 176.2, 136.5, 135.8, 133.6, 130.0, 128.9, 128.8, 128.6, 128.2,
79.0, 76.2, 59.5, 57.8, 39.8, 31.1, 29.4, 22.9; HRMS (ESI-TOF) m/z:
[M + Na]+ calcd for C22H25NNaO4, 390.1681; found, 390.1677.
4-(Benzyloxy)-2,2-dimethyl-5-(2-oxo-2-(p-tolyl)ethyl)-1,4-oxaze-
pan-3-one (8ab). Following the general procedure, reaction between
(E)-5-hydroxy-1-(p-tolyl)pent-2-en-1-one 7b (0.10 g, 0.5 mmol, 1.0
equiv) and α-bromo hydroxamate 1a (0.271 g, 1.0 mmol, 2.0 equiv)
afforded the corresponding 1,4-oxazepan-3-one 8ab, which was
purified by silica gel column chromatography (3:7 Et2O/hexane as
the eluent) to give the title compound as colorless liquid in 61%
(0.122 g) yield. Rf 0.42 (2:3 Et2O/hexane);
1H NMR (400 MHz,
CDCl3): δ 7.74 (d, J = 8.0 Hz, 2H), 7.37−7.35 (m, 2H), 7.31−7.29
(m, 3H), 7.22 (d, J = 8.0 Hz, 2H), 4.87 (d, J = 10.4 Hz, 1H), 4.81 (d,
J = 10.4 Hz, 1H), 4.51−4.45 (m, 1H), 3.81−3.76 (m, 1H), 3.65−3.58
(m, 1H), 3.36 (dd, J = 17.7, 8.9 Hz, 1H), 3.15 (dd, J = 17.7, 4.5 Hz,
1H), 2.39 (s, 3H), 2.15−2.02 (m, 2H), 1.53 (s, 3H), 1.51 (s, 3H);
13C{1H} NMR (100 MHz, CDCl3): δ 197.5, 176.2, 144.4, 135.8,
134.0, 130.0, 129.4, 128.9, 128.6, 128.3, 78.9, 76.2, 59.5, 57.9, 39.5,
31.1, 29.4, 22.8, 21.8; HRMS (ESI-TOF) m/z: [M + Na]+ calcd for
C23H27NNaO4, 404.1838; found, 404.1827.
4-(Benzyloxy)-5-(2-(4-methoxyphenyl)-2-oxoethyl)-2,2-dimethyl-
1,4-oxazepan-3-one (8ac). Following the general procedure, reaction
between (E)-5-hydroxy-1-(4-methoxyphenyl)pent-2-en-1-one 7c
(0.10 g, 0.2 mmol, 1.0 equiv) and α-bromo hydroxamate 1a (0.108
g, 0.4 mmol, 2.0 equiv) afforded the corresponding 1,4-oxazepan-3-
one 8ac, which was purified by silica gel column chromatography
(9:11 Et2O/hexane as the eluent) to give the title compound as
yellow liquid in 60% (0.058 g) yield. Rf 0.3 (2:3 Et2O/hexane);
1H
NMR (400 MHz, CDCl3): δ 7.85 (d, J = 8.7 Hz, 2H), 7.38−7.37 (m,
2H), 7.33−7.31 (m, 3H), 6.91 (d, J = 8.7 Hz, 2H), 4.89 (d, J = 10.3
Hz, 1H), 4.83 (d, J = 10.4 Hz, 1H), 4.53−4.47 (m, 1H), 3.87 (s, 3H),
3.83−3.78 (m, 1H), 3.69−3.61 (m, 1H), 3.35 (dd, J = 17.4, 8.9 Hz,
1H), 3.17 (dd, J = 17.4, 4.7 Hz, 1H), 2.14−2.04 (m, 2H), 1.55 (s,
3H), 1.53 (s, 3H); 13C{1H} NMR (100 MHz, CDCl3): δ 196.4,
176.2, 163.9, 135.8, 130.5, 130.0, 129.6, 128.9, 128.6, 113.9, 78.9,
76.2, 59.5, 58.0, 55.6, 39.4, 31.1, 29.4, 22.9; HRMS (ESI-TOF) m/z:
[M + Na]+ calcd for C23H27NNaO5, 420.1787; found, 420.1782.
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4-(Benzyloxy)-5-(2-(4-fluorophenyl)-2-oxoethyl)-2,2-dimethyl-
1,4-oxazepan-3-one (8ad). Following the general procedure,
reaction between (E)-1-(4-fluorophenyl)-5-hydroxypent-2-en-1-one
7d (0.07 g, 0.4 mmol, 1.0 equiv) and α-bromo hydroxamate 1a
(0.217 g, 0.8 mmol, 2.0 equiv) afforded the corresponding 1,4-
oxazepan-3-one 8ad, which was purified by silica gel column
chromatography (3:7 Et2O/hexane as the eluent) to give the title
compound as the white solid in 77% (0.107 g) yield. Rf 0.35 (2:3
Et2O/hexane); mp 91.6−92.8 °C; 1H NMR (400 MHz, CDCl3): δ
7.87 (dd, J = 8.4, 5.6 Hz, 2H), 7.38−7.36 (m, 2H), 7.34−7.31 (m,
3H), 7.11 (app t, J = 8.5 Hz, 2H), 4.88 (d, J = 10.5 Hz, 1H), 4.83 (d, J
= 10.5 Hz, 1H), 4.50−4.45 (m, 1H), 3.84−3.79 (m, 1H), 3.67−3.59
(m, 1H), 3.34 (dd, J = 17.8, 8.8 Hz, 1H), 3.12 (dd, J = 17.8, 4.6 Hz,
1H), 2.13−2.08 (m, 2H), 1.55 (s, 3H), 1.53 (s, 3H); 13C{1H} NMR
(100 MHz, CDCl3): δ 196.2, 176.2, 166.1 (d, J = 254.0 Hz),135.9,
132.9 (d, J = 3.0 Hz), 130.9 (d, J = 9.3 Hz), 130.0, 128.9, 128.6, 115.9
(d, J = 21.8 Hz), 79.0, 76.2, 59.4, 57.8, 39.6, 31.1, 29.4, 22.9; HRMS
(ESI-TOF) m/z: [M + Na]+ calcd for C22H24FNNaO4, 408.1587;
found, 408.1581.
4-(Benzyloxy)-5-(2-(4-bromophenyl)-2-oxoethyl)-2,2-dimethyl-
1,4-oxazepan-3-one (8ae). Following the general procedure, reaction
between (E)-1-(4-bromophenyl)-5-hydroxypent-2-en-1-one 7e (0.10
g, 0.4 mmol, 1.0 equiv) and α-bromo hydroxamate 1a (0.217 g, 0.8
mmol, 2.0 equiv) afforded the corresponding 1,4-oxazepan-3-one 8ae,
which was purified by silica gel column chromatography (3:7 Et2O/
hexane as the eluent) to give the title compound as the white solid in
75% (0.131 g) yield. Rf 0.38 (2:3 Et2O/hexane); mp 82.5−83.5 °C;
1H NMR (400 MHz, CDCl3): δ 7.69 (d, J = 8.2 Hz, 2H), 7.57 (d, J =
8.3 Hz, 2H), 7.40−7.35 (m, 2H), 7.33−7.31 (m, 3H), 4.87 (d, J =
10.6 Hz, 1H), 4.83 (d, J = 10.6 Hz, 1H), 4.49−4.44 (m, 1H), 3.84−
3.78 (m, 1H), 3.66−3.58 (m, 1H), 3.31 (dd, J = 17.8, 8.7 Hz, 1H),
3.10 (dd, J = 17.8, 4.7 Hz, 1H), 2.12−2.08 (m, 2H), 1.54 (s, 3H),
1.52 (s, 3H); 13C{1H} NMR (100 MHz, CDCl3): δ 196.8, 176.2,
135.9, 135.2, 132.1, 130.0, 129.7, 128.9, 128.8, 128.7, 79.0, 76.3, 59.4,
57.8, 39.7, 31.1, 29.4, 22.9; HRMS (ESI-TOF) m/z: [M + Na]+ calcd
for C22H24BrNNaO4, 468.0786; found, 468.0784.
4-(Benzyloxy)-5-(2-(2-bromophenyl)-2-oxoethyl)-2,2-dimethyl-
1,4-oxazepan-3-one (8af). Following the general procedure, reaction
between (E)-1-(2-bromophenyl)-5-hydroxypent-2-en-1-one 7f (0.10
g, 0.4 mmol, 1.0 equiv) and α-bromo hydroxamate 1a (0.217 g, 0.8
mmol, 2.0 equiv) afforded the corresponding 1,4-oxazepan-3-one 8af,
which was purified by silica gel column chromatography (3:7 Et2O/
hexane as the eluent) to give the title compound as colorless liquid in
70% (0.123 g) yield. Rf 0.36 (2:3 Et2O/hexane);
1H NMR (400 MHz,
CDCl3): δ 7.59 (d, J = 7.1 Hz, 1H), 7.40 (d, J = 6.8 Hz, 2H), 7.36−
7.32 (m, 3H), 7.30−7.27 (m, 3H), 4.91 (d, J = 10.5 Hz, 1H), 4.88 (d,
J = 10.5 Hz, 1H), 4.53−4.47 (m, 1H), 3.86−3.80 (m, 1H), 3.73−3.65
(m, 1H), 3.39 (dd, J = 18.0, 8.4 Hz, 1H), 3.16 (dd, J = 18.0, 5.2 Hz,
1H), 2.09−2.06 (m, 2H), 1.51 (s, 3H), 1.50 (s, 3H); 13C{1H} NMR
(100 MHz, CDCl3): δ 201.2, 175.7, 140.8, 135.6, 133.8, 131.9, 129.9,
128.8, 128.5, 127.5, 118.6, 79.0, 76.4, 59.5, 57.4, 44.0, 31.3, 28.9, 23.1;
HRMS (ESI-TOF) m/z: [M + Na]+ calcd for C22H24BrNNaO4,
468.0786; found, 468.0789.
4-(Benzyloxy)-2,2-dimethyl-5-(2-(naphthalen-2-yl)-2-oxoethyl)-
1,4-oxazepan-3-one (8ag). Following the general procedure,
reaction between (E)-5-hydroxy-1-(naphthalen-2-yl)pent-2-en-1-one
7g (0.07 g, 0.3 mmol, 1.0 equiv) and α-bromo hydroxamate 1a (0.163
g, 0.6 mmol, 2.0 equiv) afforded the corresponding 1,4-oxazepan-3-
one 8ag, which was purified by silica gel column chromatography (3:7
Et2O/hexane as the eluent) to give the title compound as yellow
liquid in 66% (0.085 g) yield. Rf 0.4 (2:3 Et2O/hexane); FT-IR (ν
cm−1): 3031, 2977, 2935, 1677, 1629, 1468, 1374, 1184, 996; 1H
NMR (400 MHz, CDCl3): δ 8.33 (s, 1H), 7.95 (d, J = 8.0 Hz, 2H),
7.88 (d, J = 8.4 Hz, 2H), 7.62 (app t, J = 7.3 Hz, 1H), 7.58 (app t, J =
7.4 Hz, 1H), 7.40−7.39 (m, 2H), 7.32−7.29 (m, 3H), 4.91 (d, J =
10.6 Hz, 1H), 4.86 (d, J = 10.5 Hz, 1H), 4.58−4.53 (m, 1H), 3.87−
3.82 (m, 1H), 3.72−3.64 (m, 1H), 3.51 (dd, J = 17.7, 8.9 Hz, 1H),
3.29 (dd, J = 17.7, 4.2 Hz, 1H), 2.21−2.12 (m, 2H), 1.59 (s, 3H),
1.55 (s, 3H); 13C{1H} NMR (100 MHz, CDCl3): δ 197.8, 176.3,
135.9, 135.8, 133.7, 132.5, 130.2, 130.1, 129.7, 128.9, 128.8, 128.6,
127.9, 127.0, 123.7, 78.9, 76.2, 59.5, 58.0, 39.6, 31.1, 29.5, 22.8;
HRMS (ESI-TOF) m/z: [M + Na]+ calcd for C26H27NNaO4,
440.1838; found, 440.1826.
4-(Benzyloxy)-2,2-dimethyl-5-(2-oxo-2-(thiophen-2-yl)ethyl)-1,4-
oxazepan-3-one (8ah). Following the general procedure, reaction
between (E)-5-hydroxy-1-(thiophen-2-yl)pent-2-en-1-one 7h (0.10 g,
0.5 mmol, 1.0 equiv) and α-bromo hydroxamate 1a (0.271 g, 1.0
mmol, 2.0 equiv) afforded the corresponding 1,4-oxazepan-3-one 8ah,
which was purified by silica gel column chromatography (3:7 Et2O/
hexane as the eluent) to give the title compound as colorless liquid in
72% (0.148 g) yield. Rf 0.42 (2:3 Et2O/hexane);
1H NMR (400 MHz,
CDCl3): δ 7.65 (d, J = 4.9 Hz, 1H), 7.62 (d, J = 3.7 Hz, 1H), 7.38 (d,
J = 6.5 Hz, 2H),7.35−7.31 (m, 3H), 7.11 (app t, J = 4.3 Hz, 1H), 4.87
(d, J = 10.3 Hz, 1H), 4.83 (d, J = 10.3 Hz, 1H), 4.51−4.46 (m, 1H),
3.84−3.79 (m, 1H), 3.72−3.64 (m, 1H), 3.33 (dd, J = 17.0, 8.6 Hz,
1H), 3.19 (dd, J = 17.0, 5.2 Hz, 1H), 2.10−2.06 (m, 2H), 1.54 (s,
3H), 1.52 (s, 3H); 13C{1H} NMR (100 MHz, CDCl3): δ 190.7,
176.2, 143.9, 135.7, 134.3, 132.5, 130.0, 128.9, 128.6, 128.3, 78.9,
76.3, 59.5, 57.9, 40.5, 31.2, 29.4, 22.9; HRMS (ESI-TOF) m/z: [M +
Na]+ calcd for C20H23NNaO4S, 396.1245; found, 396.1239.
4-Methoxy-2,2-dimethyl-5-(2-oxo-2-(thiophen-2-yl)ethyl)-1,4-
oxazepan-3-one (8bh). Following the general procedure, reaction
between (E)-5-hydroxy-1-(thiophen-2-yl)pent-2-en-1-one 7h (0.08 g,
0.4 mmol, 1.0 equiv) and α-bromo hydroxamate 1b (0.217 g, 0.8
mmol, 2.0 equiv) afforded the corresponding 1,4-oxazepan-3-one 8bh,
which was purified by silica gel column chromatography (3:7 Et2O/
hexane as the eluent) to give the title compound as the yellow solid in
69% (0.090 g) yield. Rf 0.4 (2:3 Et2O/hexane); mp 60.8−62.0 °C; 1H
NMR (400 MHz, CDCl3): δ 7.79 (d, J = 3.7 Hz, 1H), 7.68 (d, J = 4.9
Hz, 1H), 7.15 (app t, J = 4.3 Hz, 1H), 4.61−4.56 (m, 1H), 3.88−3.83
(m, 1H), 3.76−3.71 (m, 1H), 3.68 (s, 3H), 3.58 (dd, J = 16.7, 5.8 Hz,
1H), 3.45 (dd, J = 16.7, 8.1 Hz, 1H), 2.20−2.12 (m, 2H), 1.49 (s,
6H); 13C{1H} NMR (100 MHz, CDCl3): δ 190.6, 175.6, 144.0,
134.5, 132.5, 128.5, 78.9, 62.3, 59.6, 57.0, 40.9, 31.6, 29.1, 23.0;
HRMS (ESI-TOF) m/z: [M + Na]+ calcd for C14H19NNaO4S,
320.0932; found, 320.0926.
Methyl 2-(((1-((Benzyloxy)amino)-2-methyl-1-oxopropan-2-yl)-
oxy)methyl)acrylate (10a). Methyl 2-(hydroxymethyl)acrylate 9a
(0.100 g, 0.86 mmol, 1.0 equiv) and α-bromo hydroxamate 1a (0.467
g, 1.7 mmol, 2.0 equiv) were taken in HFIP (0.2 M) and was added
Na2CO3 (0.274 g, 2.6 mmol, 3.0 equiv). The reaction mixture was
stirred at room temperature for 3 h until the disappearance of the
starting materials was observed (TLC controlled). The solvent was
removed in vacuo, and the crude product was purified by silica gel
column chromatography (1:4 EtOAc/hexane as the eluent) to give
the title compound as colorless oil 10a in 89% (0.235 g) yield. Rf 0.4
(3:7 EtOAc/hexane); 1H NMR (400 MHz, CDCl3): δ 10.34 (s, 1H),
7.41 (d, J = 7.1 Hz, 2H), 7.33−7.28 (m, 3H), 6.24 (s, 1H), 5.78 (s,
1H), 4.93 (s, 2H), 3.96 (s, 2H), 3.71 (s, 3H), 1.39 (s, 6H); 13C{1H}
NMR (100 MHz, CDCl3): δ 171.7, 166.7, 136.3, 135.4, 129.3, 129.0,
128.5, 128.3, 79.1, 77.8, 63.8, 52.2, 24.5; HRMS (ESI-TOF) m/z: [M
+ Na]+ calcd for C16H21NNaO5, 330.1317; found, 330.1313.
N-(Benzyloxy)-2-methyl-2-(2-methylene-3-oxobutoxy)-
propanamide (10b). Compound 9b (0.05 g, 0.5 mmol, 1.0 equiv)
and α-bromo hydroxamate 1a (0.467 g, 1.0 mmol, 2.0 equiv) were
taken in HFIP (0.2 M) and was added Na2CO3 (0.159 g, 1.5 mmol,
3.0 equiv). The reaction mixture was stirred at room temperature for
5 h until the disappearance of the starting materials was observed
(TLC controlled). The solvent was removed in vacuo, and the crude
product was purified by silica gel column chromatography (7:3 Et2O/
hexane as the eluent) to give the title compound 10b as colorless oil
in 85% (0.124 g) yield. Rf 0.4 (7:3 Et2O/hexane); δ
1H NMR (400
MHz, CDCl3): δ 10.39 (s, 1H), 7.44 (d, J = 6.9 Hz, 2H), 7.35−7.29
(m, 3H), 6.14 (s, 1H), 5.99 (s, 1H), 4.97 (s, 2H), 3.95 (s, 2H), 2.34
(s, 3H), 1.39 (s, 6H); 13C{1H} NMR (100 MHz, CDCl3): δ 199.8,
171.9, 144.6, 135.5, 129.6, 129.4, 128.6, 128.5, 79.3, 77.9, 63.4, 26.0,
24.7; HRMS (ESI-TOF) m/z: [M + Na]+ calcd for C16H21NNaO4,
314.1368; found, 314.1366.
Methyl 4-(Benzyloxy)-2,2-dimethyl-3-oxo-1,4-oxazepane-6-car-
boxylate (11a). Compound 10a (0.05 g, 0.16 mmol, 1.0 equiv)
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was taken in MeOH (0.2 M) and was added Et3N (30 μL, 0.18 mmol,
1.1 equiv) dropwise. The reaction mixture was stirred at 60 °C
overnight until the disappearance of the starting materials was
observed (TLC controlled). The solvent was removed in vacuo, and
the crude product was purified by silica gel column chromatography
(1:5 EtOAc/hexane as the eluent) to give the title compound as white
solid 11a in 66% (0.033 g) yield. Rf 0.5 (3:7 EtOAc/hexane); mp
85.4−86.5 °C; 1H NMR (400 MHz, CDCl3): δ 7.45−7.43 (m, 2H),
7.40−7.37 (m, 3H), 5.00 (d, J = 10.3 Hz, 1H), 4.92 (d, J = 10.3 Hz,
1H), 4.07 (dd, J = 14.9, 8.2 Hz, 1H), 3.99 (dd, J = 13.1, 5.0 Hz, 1H),
3.84−3.74 (m, 2H), 3.69 (s, 3H), 2.77−2.71 (m, 1H), 1.46 (s, 3H),
1.45 (s, 3H); 13C{1H} NMR (100 MHz, CDCl3): δ 172.4, 171.9,
135.4, 129.9, 129.1, 128.7, 81.5, 76.7, 62.7, 52.4, 50.7, 43.4, 25.9, 25.0;
HRMS (ESI-TOF) m/z: [M + Na]+ calcd for C16H21NNaO5,
330.1317; found, 330.1308.
6-Acetyl-4-(benzyloxy)-2,2-dimethyl-1,4-oxazepan-3-one (11b).
Following the same procedure as was used for the preparation of
11a, compound 10b (0.05 g, 0.17 mmol) was transformed into
compound 11b as colorless oil in 58% (0.029 g) yield. Rf 0.4 (2:3
EtOAc/hexane); 1H NMR (400 MHz, CDCl3): δ 7.44−7.42 (m,
2H), 7.40−7.36 (m, 3H), 4.99 (d, J = 10.5 Hz, 1H), 4.91 (d, J = 10.5
Hz, 1H), 4.00 (dd, J = 15.0, 8.4 Hz, 1H), 3.92 (dd, J = 13.1, 5.1 Hz,
1H), 3.77−3.68 (m, 2H), 2.73−2.66 (m, 1H), 2.11 (s, 3H), 1.45 (s,
6H); 13C{1H} NMR (100 MHz, CDCl3): δ 206.3, 172.3, 135.5,
130.0, 129.1, 128.7,81.3, 76.7, 62.1, 51.2, 50.6, 28.8, 26.0, 25.0;




one 12 (0.100 g, 0.45 mmol, 1.0 equiv) and α-bromo hydroxamate 1a
(0.121 g, 0.45 mmol, 1.0 equiv) were taken in HFIP (0.2 M) and was
added Na2CO3 (0.142 g, 1.34 mmol, 3.0 equiv). The reaction mixture
was stirred at room temperature for 7 h until the disappearance of the
starting materials was observed (TLC controlled). The solvent was
removed in vacuo, and the crude product was purified by silica gel
column chromatography (1:4 EtOAc/hexane as the eluent) to give
the title compound as white solid 13 in 65% (0.120 g) yield. Rf 0.4
(3:7 EtOAc/hexane); mp 167.1−168.8 °C; 1H NMR (400 MHz,
CDCl3): δ 7.67−7.65 (m, 2H), 7.43−7.40 (m, 3H), 7.37 (d, J = 7.7
Hz, 1H), 7.29−7.22 (m, 5H), 7.16−7.09 (m, 2H), 6.89 (t, J = 7.5 Hz,
1H), 6.83 (d, J = 8.1 Hz, 1H), 6.68 (d, J = 16.2 Hz, 1H), 6.11 (br s,
1H), 4.99 (d, J = 9.4 Hz, 1H), 4.58 (d, J = 9.4 Hz, 1H), 1.54 (s, 3H),
1.49 (s, 3H); 13C{1H} NMR (100 MHz, CDCl3): δ 170.5, 154.2,
140.0, 134.1, 129.8, 129.6, 129.3, 129.0, 129.0(2), 128.7, 128.6, 128.5,
128.3, 127.3, 123.0, 120.7, 116.3, 93.4, 79.0, 78.2, 26.1, 25.6; HRMS




(E)-3-(2-Hydroxyphenyl)-1-phenylprop-2-en-1-one 12 (0.100 g, 0.45
mmol, 1.0 equiv) and α-bromo hydroxamate 1a (0.121 g, 0.45 mmol,
1.0 equiv) were taken in HFIP (0.2 M) and was added Na2CO3
(0.142 g, 1.34 mmol, 3.0 equiv). The reaction mixture was stirred at
room temperature for 7 h until the disappearance of the starting
materials was observed (TLC controlled). The solvent was removed
in vacuo, and the crude product was purified by silica gel column
chromatography (3:7 EtOAc/hexane as the eluent) to give the title
compound as yellow liquid 14 in 25% (0.068 g) yield. Rf 0.37 (3:7
EtOAc/hexane); 1H NMR (400 MHz, CDCl3): δ 9.00 (s, 1H), 7.67−
7.65 (m, 2H), 7.50−7.44 (m, 4H), 7.39−7.36 (m, 5H), 7.30−7.26
(m, 5H), 7.19−7.03 (m, 3H), 6.79 (d, J = 8.2 Hz, 1H), 6.52 (d, J =
16.3 Hz, 1H), 5.01 (d, J = 9.4 Hz, 1H), 4.94 (s, 2H), 4.50 (d, J = 9.3
Hz, 1H), 1.53 (s, 6H), 1.41 (s, 3H), 1.39 (s, 3H); 13C{1H} NMR
(100 MHz, CDCl3): δ 172.1, 170.2, 152.1, 139.7, 135.0, 134.1, 129.8,
129.4, 129.2, 129.1, 128.9, 128.7, 128.5, 128.5(2), 128.3, 127.2, 123.5,
120.3, 93.0, 82.1, 78.9, 78.3, 78.0, 26.2, 25.6, 25.3, 25.2; HRMS (ESI-
TOF) m/z: [M + Na]+ calcd for C37H38N2NaO6, 629.2628; found,
629.2612.
4-Hydroxy-5-(2-hydroxy-2-phenylethyl)-2,2-dimethylmorpholin-
3-one (15). Palladium on carbon (10% w/w, 0.03 g) was added to a
solution of 3aa (0.10 g, 0.3 mmol) in MeOH (3.0 mL), and the
mixture was stirred at room temperature under a hydrogen balloon for
20 h. The mixture was then filtered through Celite and thoroughly
washed with ethyl acetate. Then, the filtrate was concentrated under
vacuo, and the resulting residue was purified by silica gel column
chromatography (3:7 EtOAc/hexane) to afford 15 as the yellow solid
in 48% (0.064 g) yield. Rf 0.25 (3:7 EtOAc/hexane); mp 108.5−109.5
°C; 1H NMR (400 MHz, CDCl3): δ 7.39−7.36 (m, 4H), 7.30−7.28
(m, 1H), 5.05 (dd, J = 9.7, 2.8 Hz, 1H), 4.08 (dd, J = 12.1, 3.1 Hz,
1H), 4.02−3.96 (m, 1H), 3.83 (dd, J = 12.1, 2.6 Hz, 1H), 2.31−2.25
(m, 1H), 2.16−2.08 (m, 1H), 1.45 (s, 6H); 13C{1H} NMR (100
MHz, CDCl3): δ 168.2, 144.1, 128.8, 128.0, 125.7, 77.6, 72.0, 63.5,
57.9, 40.6, 26.2, 24.1; HRMS (ESI-TOF) m/z: [M + Na]+ calcd for
C14H19NNaO4, 288.1212; found, 288.1201.
6,6-Dimethyl-2-phenyltetrahydroisoxazolo[3,2-c][1,4]oxazin-
7(6H)-one (16). To a cooled (0 °C) solution of 15 (0.05 g, 1.0 mmol)
and PPh3 (0.066 g, 1.2 mmol) in DCM (10 mL) was added a solution
of ditert-butyl azodicarboxylate (0.056 g, 1.2 mmol) in DCM (2.0
mL) slowly via a syringe pump over a period of 30 min. The reaction
was slowly warmed to room temperature and stirred for 16 h. The
solvent was removed in vacuo, and the crude product was purified by
silica gel column chromatography (1:4 EtOAc/hexane as eluent) to
give the title compound as yellow liquid 16 in 68% (0.032 g) yield. Rf
0.38 (3:7 EtOAc/hexane); 1H NMR (400 MHz, CDCl3): δ 7.42 (d, J
= 7.3 Hz, 2H), 7.38−7.30 (m, 3H), 5.36 (dd, J = 9.0, 6.1 Hz, 1H),
4.40−4.32 (m, 1H), 4.14 (dd, J = 11.7, 4.2 Hz, 1H), 3.53 (dd, J =
11.7, 10.1 Hz, 1H), 2.82−2.76 (m, 1H), 2.08−2.00 (m, 1H), 1.51 (s,
3H), 1.45 (s, 3H); 13C{1H} NMR (100 MHz, CDCl3): δ 165.8,
137.9, 128.9, 128.8, 126.2, 81.4, 78.5, 64.7, 59.4, 40.1, 27.3, 23.3;
HRMS (ESI-TOF) m/z: [M + Na]+ calcd for C14H17NNaO3,
270.1106; found, 270.1101.
5-(2-(2-Bromophenyl)-2-oxoethyl)-2,2-dimethyl-1,4-oxazepan-
3-one (17). To a solution of 8af (0.11 g, 0.25 mmol, 1.0 equiv) in
acetonitrile/water (9:1, 2 mL), Mo(CO)6 (0.078 g, 0.3 mmol, 1.2
equiv) was added, and the reaction was stirred at 120 °C under argon
for 12 h. After cooling to room temperature, the mixture was then
filtered through Celite and thoroughly washed with ethyl acetate.
Then, the filtrate was concentrated under vacuo, and the resulting
residue was purified by silica gel column chromatography (3:7
EtOAc/hexane) to afford 17 as the white solid in 70% (0.059 g) yield.
Rf 0.25 (3:7 EtOAc/hexane); mp 110.5−111.5 °C; 1H NMR (400
MHz, CDCl3): δ 7.61 (d, J = 7.9 Hz, 1H), 7.44−7.36 (m, 2H), 7.31
(t, J = 7.6 Hz, 1H), 6.31 (d, J = 3.4 Hz, 1H), 4.49−4.41 (m, 1H),
3.93−3.88 (m, 1H), 3.73−3.66 (m, 1H), 3.22−3.20 (m, 2H), 2.18−
2.09 (m, 1H), 1.76−1.69 (m, 1H), 1.42 (s, 6H); 13C{1H} NMR (100
MHz, CDCl3): δ 201.3, 178.1, 141.0, 133.9, 132.2, 128.8, 127.8,
118.8, 81.5, 61.3, 47.2, 46.1, 34.9, 26.1, 25.1; HRMS (ESI-TOF) m/z:
[M + Na]+ calcd for C15H18BrNNaO3, 362.0368; found, 362.0353.
2,2-Dimethyl-4,5,5a,6-tetrahydro-1H-[1,4]oxazepino[4,5-a]-
quinoline-1,7(2H)-dione (18). Pd(OAc)2 (0.005 g, 0.007 mmol),
Cu(OAc)2 (0.014 g, 0.075 mmol), and K2CO3 (0.069 g, 0.5 mmol)
were added under an Ar atmosphere to a stirred solution of 17 (0.05
g, 0.15 mmol) in toluene (3.0 mL). The mixture was heated at reflux
for 24 h, allowed to cool, and filtered through a Celite pad. The
filtrate was concentrated to give a crude product, which was purified
by silica gel column chromatography (1:4 EtOAc/hexane) to afford
18 as the yellow solid in 56% (0.021 g) yield. Rf 0.35 (3:7 EtOAc/
hexane); mp 116.8−118.0 °C; FT-IR (ν cm−1): 2931, 1672, 1599,
1477, 1458, 1264, 1192, 1089; 1H NMR (400 MHz, CDCl3): δ 7.99
(d, J = 7.8 Hz, 1H), 7.88 (d, J = 8.7 Hz, 1H), 7.48 (t, J = 7.9 Hz, 1H),
7.11 (t, J = 7.5 Hz, 1H), 4.65−4.59 (m, 1H), 3.92−3.86 (m, 1H),
3.81−3.75 (m, 1H), 2.93 (dd, J = 16.8, 5.0 Hz, 1H), 2.82 (dd, J =
16.8, 8.0 Hz, 1H), 2.16−2.08 (m, 1H), 2.00−1.92 (m, 1H), 1.64 (s,
3H), 1.60 (s, 3H); 13C{1H} NMR (100 MHz, CDCl3): δ 192.6,
179.9, 144.2, 135.2, 127.4, 123.4, 123.0, 121.0, 81.8, 61.3, 52.8, 43.0,
32.3, 28.3, 25.2; HRMS (ESI-TOF) m/z: [M + Na]+ calcd for
C15H17NNaO3, 282.1106; found, 282.1095.
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